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Abstract
Objective—11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) regenerates active cortisol
from inert cortisone in adipose tissue. Elevated adipose tissue 11βHSD1 activity is observed in
obese humans and rodents where it is linked to obesity and its metabolic consequences.
Menopause is also associated with increased abdominal fat accumulation suggesting that estrogen
is also important in adipose tissue metabolism. The purpose of this current study was to establish
whether estrogen signalling through estrogen receptors-α and -β (ERα and ERβ) can influence
11βHSD1 in premenopausal and postmenopausal adipose tissue.
Methods—19 premenopausal (aged 26±5, BMI 23.6±1.6) and 23 postmenopausal healthy
women (aged 63±4, BMI 23.4±1.9) were studied. Subcutaneous adipose tissue biopsies and
fasting venous blood samples were taken. Body composition was measured by bio-electrical
impedance analysis. Human SGBS adipocyte cells were treated with ERα and ERβ-specific
agonists for 24h. Basic anthropometric data, Serum 17β-estradiol and progesterone concentrations,
ERα and ERβ mRNA levels and 11βHSD1 mRNA, protein and activity levels were assessed.
Results—ERβ and 11βHSD1, but not ERα mRNA was significantly increased in adipose tissue
from postmenopausal women compared to premenopausal women. ERβ had a significant positive
correlation with the mRNA level of 11βHSD1 in adipose tissue from pre- and postmenopausal
women. This association between ERβ and 11βHSD1 was greatest in adipose tissue from
postmenopausal women. In human SGBS adipocytes, diarylpropiolnitrile (DPN), a selective ERβ
agonist increased 11βHSD1 mRNA, protein and activity levels.
Conclusions—We conclude that in adipose tissue, ERβ-mediated estrogen-signalling can
upregulate 11βHSD1 and that this may be of particular importance in postmenopausal women.
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Introduction
The onset of menopause is associated with an accumulation of adipose tissue1 and this may
contribute to the increased metabolic and cardiovascular risk seen in postmenopausal
women. Chronic glucocorticoid excess (e.g. in Cushing’s syndrome) also causes obesity and
its associated metabolic dysfunction. Whilst plasma cortisol levels are not elevated in
obesity2, recent evidence suggests that there is a selective increase in glucocorticoid
regeneration in adipose tissue3. Specifically, the microsomal enzyme 11β-hydroxysteroid
dehydrogenase type 1 (11βHSD1) which catalyses the intracellular reactivation of cortisol
from inert cortisone, is selectively increased in adipose tissue in obese humans and in rodent
models of obesity4;5. This appears to be of pathophysiological importance since mice
engineered to selectively over-express 11βHSD1 in adipose tissue develop visceral obesity
and metabolic syndrome6, whereas mice lacking 11βHSD1 resist glucose intolerance,
insulin resistance and hyperlipidemia on high-fat diet7. In humans, 11βHSD1 inhibition has
analogous effects8.
Estrogen signalling is predominantly mediated via the two nuclear estrogen receptors α and
β (ERα and ERβ), both of which are present in human adipose tissue9. Human studies on
sex steroid control of 11βHSD1 in adipose tissue are scarce and inconclusive; reporting both
up-regulation and no effect of estrogen, using a variety of doses mainly in vitro10. Here we
have explored the possibility of a functional link between ERα/β signalling and 11βHSD1
expression/activity in adipose tissue from premenopausal and postmenopausal women.
Methods
Experiments in Humans
All women gave written, informed consent and all clinical investigation was conducted
according to the principles expressed in the Declaration of Helsinki. The study of pre- and
postmenopausal women was approved by the Ethical Committee for human research at
Umeå University, Umeå, Sweden, approval ID 03-339. 19 premenopausal and 23
postmenopausal, healthy, normal weight women were recruited by advertisements in the
local newspapers and within the Umeå University Hospital and campus areas. Exclusion
criteria were: diabetes, thyroid dysfunction, hepatic and renal disease, use of tobacco,
hormonal contraceptives, systemic gonadal hormone replacement therapy, or oral
glucocorticoid medication. None of the postmenopausal women reported menstrual periods
within the last 12 months. One premenopausal woman used inhaled steroids for asthma
(budesonide, 400 μg/24 h). Three postmenopausal women had well-controlled hypertension
treated with β-blockers, diuretics, or calcium antagonist, one took tolterodine for urinary
incontinence and bisphosphonates for osteoporosis, and two used topical E2 or estriol
treatment. Further details of the participants included in this study have been described
previously11.
Clinical protocol—Premenopausal women were evaluated during the follicular phase of
the menstrual cycle to negate the possible effects of hormonal fluctuations. Menstrual phase
or postmenopausal status was confirmed by measuring serum 17β-estradiol and
progesterone levels (described below).
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Anthropometric measurements and adipose tissue biopsies were performed on separate days.
Weight to the nearest 0.1 kg (with subjects wearing light clothes) and height and waist
circumference to the nearest 0.5 cm was measured. Body composition was measured by bio-
electrical impedance analysis using a Bodystat 1500 (Bodystat Ltd., Isle of Man, British
Isles). Approximately 2 g of periumbilical superficial subcutaneous adipose tissue was
excised under local anaesthesia with lidocaine (Xylocaine® without adrenaline,
AstraZeneca, Sweden) after an overnight fast. Tissue was snap frozen in liquid nitrogen
within 5 minutes after removal, and stored at −80°C until further analyses.
Venous blood samples for routine laboratory tests were drawn at the time of anthropometric
measurements. Venous blood samples for serum analyses (described below) were drawn in
the mornings of the adipose tissue biopsies after at least eight hours of fasting.
Laboratory methods
Serum Analyses—17β-Estradiol, progesterone and cortisol were measured in samples
drawn at the time of the biopsy. Serum cortisol and progesterone were analyzed by
electrochemiluminescence immunoassays, on a Modular Analytics E170 (all from Roche
AB, Stockholm, Sweden). 17β-Estradiol was measured using an ultra sensitive
radioimmunoassay (ESTR-US-CT, CIS bio international, Gif-sur-Yvette, Cedex, France)
(intra- and interassay coefficients of variation (CV); 2.8–18.1% and 5.8–17.6%,
respectively).
Cell culture—Human SGBS (Simpson-Golabi-Behmel Syndrome) adipocyte cells which
have previously been shown to express both ERα and ERβ12 were maintained and
differentiated into adipocytes, as previously described13. For experimental manipulations,
cells were serum-starved overnight in phenol-red-free medium containing 0.1% BSA. After
serum starvation, cells were treated with diarylpropiolnitrile (DPN) or propyl-pyrazole triol
(PPT), at the concentrations indicated for 24 h. All experiments were performed in triplicate
and repeated three times.
Quantification of mRNA—Total RNA was extracted from snap-frozen adipose tissue or
SGBS adipocytes according to the manufacturer’s protocol using the RNeasy® lipid tissue
midi kit (Qiagen Nordic, Qiagen House, West Sussex, UK). RNA concentrations were
measured on a ND-1000 Spectrophotometer (NanoDrop Technologies, Bancroft Building,
Wilmington, DE, USA) and integrity was evaluated on a 1% agarose electrophoretic gel and
visualized with ethidium bromide under UV-light.
One microgram of RNA was reverse transcribed into cDNA using TaqMan® Reverse
Transcription Reagents (Roche Molecular Systems, Inc., Branchburg, NJ, USA). cDNA was
incubated in triplicate with 1x gene-specific assay mix (Applied Biosystems, Warrington,
UK) in 1x Universal PCR Master Mix (Roche). PCR cycling and detection of fluorescent
signal was carried out on an ABI Prism® 7000 Sequence Detection System (Applied
Biosystems). Triplicates were deemed acceptable if the standard deviation of the crossing
point was < 0.5 cycles. A standard curve (y axis crossing point, x axis log concentration) for
each gene was generated by serial dilution of cDNAs pooled from different samples and
fitted with a straight line and deemed acceptable if reaction efficiency was between 1.7 and
2.1. For SGBS cells, results were corrected for with TATA box binding protein (TBP) and
for human adipose tissue, results were corrected for cyclophilin A which had the lowest
coefficients of variation and the best stability value, based on the Normfinder algorithm
(http://www.mdl.dk/publicationsnormfinder.htm) out of three tested endogenous controls.
The prevalidated assays used were: human ERα, Hs00174860_m1; human ERβ,
Hs00230957_m1; human 11βHSD1, Hs01547870_m1; and the endogenous controls
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cyclophilin A (PPIA), Hs99999904_m1 and TBP Hs00427620_m1; (all from Applied
Biosystems).
Western blot—SGBS cells were washed in ice-cold PBS and lysates prepared as described
previously13. 50μg of protein were diluted in sample buffer containing DTT, denatured and
run on 12% polyacrylamide gels, and transferred to nitrocellulose for Western blotting.
Membranes were probed with 11βHSD1 antibody (The Binding Site Group Ltd,
Birmingham, UK). Protein loaded was corrected for using a monoclonal antibody against β-
tubulin (Millipore, Watford, UK). Proteins were visualised with an Alexa Fluor® secondary
antibody (Li-cor Biosciences, Cambridge, UK) and band intensities were quantified using
the Odyssey infrared imaging system (Li-cor Biosciences).
Enzymology—11βHSD1 activity was measured in the 11β-reductase direction in intact
differentiated SGBS adipocytes. 3 × 105 cells/ well in 6-well plates were differentiated as
described above. Each well was incubated at 37°C in 2ml of serum - and phenol-red-free
medium containing 1pM [3H]-cortisone (GE Healthcare; Aylesbury, UK) and 1μM
cortisone (Sigma-Aldrich Company Ltd, Dorset, UK). All incubations were performed in
triplicate for 24h. Assay conditions were optimized to ensure first-order kinetics. After
incubation steroids were extracted from 2ml of medium with Sep-pak columns (C18, 0.3g,
Waters, Milford, MA, USA). The organic phase was evaporated under nitrogen and extracts
were re-suspended in mobile phase (60% water, 10% acetonitrile, 30% methanol).
Percentage recovery was 90 ± 2.3% for cortisone and 92 ± 3.1% for cortisol. Steroids were
separated by HPLC (Waters) and compared to known tritiated standards (GE Healthcare)
using a C18 Reverse-phase column (Sunfire C18,15cm,id 2.6mm, pore size 5μm; Waters)
and were quantified by on-line liquid scintillation counting.
Statistical analyses
Data are presented as mean ± SEM, unless stated otherwise, and were natural log-
transformed when necessary to achieve parametric distributions. Unpaired Student’s t-tests
were used to compare means between groups. Associations between parameters were
assessed using Pearson correlation (r). Partial correlation analysis was used in all groups to
adjust for obesity measures. Statistical calculations were performed using the SPSS software
(release 14.0.1, SPSS Inc., 233 S. Wacker Drive, Chicago, IL). P<0.05 was considered
statistically significant.
Results
Participant characteristics
The percentage of body fat and waist-hip-ratio was significantly higher in postmenopausal
women compared to premenopausal women (Table 1). Serum E2 and progesterone levels
were significantly lower in postmenopausal vs. premenopausal women regardless of
menstrual phase (Table 1). Serum cortisol levels were not different between pre- and
postmenopausal women. Notably, there was a high variability regarding ERβ and 11βHSD1
expression in the postmenopausal study group.
ERβ and 11βHSD1 mRNA levels are increased in adipose tissue from postmenopausal
women
There was no difference in the level of ERα mRNA between pre- and postmenopausal
women, (Figure 1A). The expression level of ERβ and 11βHSD1 mRNA was two-fold
higher in postmenopausal women compared to premenopausal women in follicular phase
(Figure 1A).
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11βHSD1 mRNA is correlated with ERβ but not ERα mRNA in adipose tissue
A strong positive correlation between 11βHSD1 and ERβ mRNA levels was observed in
subcutaneous adipose tissue irrespective of menopausal status (Figure 1B). These
associations remained after adjustments for obesity measures, (BMI, waist and fat
percentage). In contrast, no association between ERα and 11βHSD1 expression was found
(Figure 1C).
Adipocyte 11βHSD1 expression and activity is up-regulated by an ERβ-agonist in vitro
The ERβ-specific agonist, DPN, up-regulated 11βHSD1 mRNA in human SGBS adipocytes
(Figure 2A). In contrast, the ERα-specific agonist PPT did not have any effect on 11βHSD1
mRNA levels (Figure 2A). 11βHSD1 protein expression (Figure 2B) and activity (Figure
2C) were also increased by DPN.
Discussion
These results identify a potential mechanism by which estrogens acting via ERβ may
enhance local glucocorticoid action in adipose tissue of postmenopausal women, involving
up-regulation of adipose 11βHSD1 expression. This association between ERβ and
11βHSD1 was greatest in adipose tissue from postmenopausal women. Crucially, a direct
effect of selectively activating ERβ on adipocyte 11βHSD1 expression and activity was
demonstrated in vitro.
In postmenopausal women, where ovarian steroid biosynthesis has ceased, the major source
of estrogens is local aromatase expression in the adipose tissue, the function of which
increases with age14. We previously reported a positive association between aromatase and
11βHSD1 gene expression in adipose tissue suggesting an up-regulatory effect of local
estrogen production on 11βHSD1 expression in adipose tissue11. Estrogen signalling is
predominantly mediated via the two nuclear receptors ERα and ERβ, both of which are
present in human adipose tissue9. Here, we have shown that ERβ mRNA levels are two-fold
higher in subcutaneous adipose tissue from postmenopausal women compared to
premenopausal women and that expression of this receptor is strongly correlated with
adipose expression of 11βHSD1. Consequently, in postmenopausal women, adipose
11βHSD1 may be increased by local estrogens acting via ERβ, resulting in increased levels
of active glucocorticoids in adipose tissue. Since increased glucocorticoid activity in adipose
tissue is associated with obesity4, this mechanism may contribute to the increase in body fat
observed in our cohort of postmenopausal women. Furthermore, aromatase promoter
activity is driven by glucocorticoids hence increased 11βHSD1 activity in adipose tissue
will further amplify this process. The reasons for the high variability in ERβ and 11βHSD1
gene expression among postmenopausal women is not clear and needs further studies
regarding putative regulatory factors including a possible interaction with aromatase
activity.
Despite a significant increase in percentage fat mass and waist-hip ratio in the
postmenopausal women the BMI of both groups of women were in the normal range
probably reflecting a decrease in lean mass and bone mineral density which is commonly
associated with menopause15. 11βHSD1 activity has been shown to be increased in adipose
tissue of even moderately obese women4 On the other hand it has been reported that there is
no significant correlation between the respective levels of ERα or ERβ in subcutaneous or
omental adipose tissue with obesity16. We have had an opportunity to assess this correlation
in subcutaneous and visceral adipose tissue of obese premenopausal women and there
remains a strong association between ERβ and 11βHSD1 in both depots (unpublished
results). Therefore, we would predict that the correlation would still remain between ERβ
McInnes et al. Page 5
Menopause. Author manuscript; available in PMC 2013 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
and 11βHSD1 in obese women. Unfortunately we did not have the opportunity to assess
whether there is an association between ERβ and 11βHSD1 expression in visceral adipose
tissue in this cohort of women. This would have been interesting since redistribution of
adipose tissue to abdominal visceral depots is commonly observed with menopause. Several
human studies have shown higher expression of 11βHSD1 in the subcutaneous depot than
other depots. Furthermore, the subcutaneous depot appears to be more predictive for obesity
and metabolic parameters17. Importantly, subcutaneous 11βHSD1 correlates with measures
of central fat accumulation and is an independent predictor for central fat accumulation17,
emphasizing the important role of the 11βHSD1 enzyme in subcutaneous adipose tissue.
This observation of a pro-adipogenic role for ERβ is supported by studies in knock-out
mice. ERα knock-out (αERKO) and double knock-out (α/βERKO) mice show marked
obesity18;19 whereas ERβ knock-out (βERKO) mice are normal weight. However, αERKO
mice also have elevated 17β-estradiol levels thus increasing ERβ signalling20 and when
ERβ signalling is removed in αERKO by ovariectomy, the fat-pad weights and adipocyte
size decrease20, suggesting adipogenic effects of ERβ signalling. Furthermore, in humans,
Shin and colleagues reported that subjects with more ERβ than ERα in omental adipose
tissue had a greater degree of adiposity16.
In vitro, the ERβ agonist, DPN had a maximal effect on 11βHSD1 at 1-10nM. Since DPN
has its highest specificity for ERβ at these concentrations21, these results support our
conclusion that activation of ERβ can directly up-regulate 11βHSD1 in adipocytes. These
findings are also supported by previous data showing that 17β-estradiol can activate the
11βHSD1 promoter in transfected adipocytes22.
Conclusion
In conclusion, this study implies a link between adipose ERβ signalling and local
glucocorticoid metabolism that may promote adipogenesis. This is particularly relevant in
the postmenopausal setting where the beneficial effects of activating ERα are diminished
due to a decrease in circulating 17β-estradiol levels and may contribute to the increase in
obesity observed in postmenopausal women.
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Figure 1. A strong positive correlation between 11βHSD1 and ERβ in adipose tissue
(A) ERα, ERβ and 11βHSD1 mRNA expression in SAT from premenopausal women in
follicular phase of the menstrual cycle compared to postmenopausal women. Data are mean
± standard error, n=19 for premenopausal women and n=23 for postmenopausal women.
*P<0.05 vs premenopause. (B) Correlations between ERβ and 11βHSD1 in SAT from pre-
and postmenopausal women (n=19 for premenopausal women and n=23 for postmenopausal
women). Closed circles represent premenopausal women and open squares represent
postmenopausal women where r = 0.53, P <0.05 for premenopausal women and r = 0.66,
P<0.0001 for postmenopaisal women. (C) Correlations between ERα and 11βHSD1 in SAT
from pre- and postmenopausal women (n=19 for premenopausal women and n=23 for
postmenopausal women). Closed circles represent premenopausal women and open squares
represent postmenopausal women where r = 0.22 for premenopausal women and r = −0.01
for postmenopaisal women. SAT, subcutaneous adipose tissue; ER, estrogen receptor ; r ,
Pearson correlation coefficient; 11βHSD1, 11β-Hydroxysteroid dehydrogenase type 1;
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Figure 2. 11βHSD1 expression and activity is up-regulated by an ERβ-specific agonist in vitro
(A) 11βHSD1 gene expression in SGBS cells after incubation with the ERβ-specific agonist
DPN. Data are mean ± standard error, n=3 triplicates. **P<0.01 vs vehicle. (B)
Representative Western blot of 11βHSD1 protein expression normalized against β-tubulin,
Data are mean ± standard error, n=3 triplicates. *P<0.05 vs vehicle (v) (C) 11βHSD1
enzyme activity in intact cells after DPN stimulation measured as % conversion of cortisone
(E) to cortisol (F) after 24h incubation. Data are mean ± standard error. n=3 triplicates.
**P<0.01 vs vehicle (v). ER, estrogen receptor ; 11βHSD1, 11β-Hydroxysteroid
dehydrogenase type 1; DPN, diarylpropionitrile; SGBS, Simpson-Golabi-Behmel
Syndrome.
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TABLE 1
Participant characteristics
Premenopausal (n = 19) Postmenopausal (n = 23)
Age, y 26 ± 5 63 ± 4a
Body fat, % 27.4 ± 3.4 36.0 ± 5.3a
Body mass index, kg/m2 23.6 ± 1.6 23.4 ± 1.9
Waist circumference, cm 80.1 ± 6.8 82.8 ± 5.5
Waist-hip ratio 0.80 ± 0.06 0.84 ± 0.05b
Cortisol, nM 476 ± 184 472 ± 141
Estradiol, pM 201 ± 142 19.6 ± 6.3a
Progesterone, nM 2.30 ± 0.79 1.32 ± 0.47a
Data are expressed as mean ± SD.
aP < 0.001 versus premenopausal women.
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